Why the Peptide Boom Reminds Me of the Early Cannabis Days

I’ve spent over a decade working with cannabis operators. So when I started watching the peptide industry take off, I got a strange feeling that I’d seen this movie before.

The rules keep changing. The banks won’t call you back. One state says “yes” while the state next door says “absolutely not”. And the businesses growing the fastest are also the ones most likely to get a knock on the door by the FDA.

Sound familiar? It should. Here’s what’s happening and why I think peptide founders should pay close attention to the cannabis playbook before they make the same mistakes.

Peptide Companies Are Popping Up Everywhere

First, let’s talk about how big this thing has gotten.

Peptides are just short chains of amino acids. Your body makes them naturally. Some of the most famous drugs on the planet are peptides, including Ozempic and Wegovy. So is Mounjaro. These are the weight-loss and diabetes drugs everyone’s talking about.

The numbers are wild. The global peptide market was worth about $141 billion in 2025, with North America holding roughly 62% of it. And it’s still climbing fast. Just look at Eli Lilly. The company pulled in around $45 billion in 2024 and guided toward $58 to $61 billion for 2025, mostly on the back of one peptide drug. Tirzepatide, the active ingredient in Mounjaro and Zepbound, is the best-selling new drug launch in history.

But the big pharma giants are just the top layer. Underneath them is a whole world of smaller players. Hundreds of telehealth companies now prescribe peptides online. Tens of thousands of wellness clinics and medspas offer peptide therapy. And compounding pharmacies are building peptide programs across the country.

Then there’s the online side, which is where things get really interesting.

People are buying peptides over the internet at a pace that’s hard to believe. LegitScript, a company that tracks this stuff, found 308% more ads for problematic peptides in 2024 than in 2023, and 678% more than in 2022. Online marketplaces saw peptide product sales grow 276% over five years. That’s not slow growth. That’s a stampede.

So you’ve got mainstream drugs, a booming wellness scene, and an ecommerce market on fire. Demand is clearly there. The question is whether the businesses chasing it can survive the mess of rules around them.

This All Feels Like Cannabis Ten Years Ago

Here’s the thing: A booming market with no clear rulebook is exactly what cannabis looked like in the early 2010s. Lots of money, lots of confusion, and lots of people getting burned because they didn’t see the legal and financial traps coming.

Let me walk you through the parallels, because they’re almost spooky.

The Rules Change in Real Time

With cannabis and hemp, federal policy shifted constantly. A single announcement could change what was possible overnight. Peptides are the same way right now.

In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that about 14 of 19 restricted peptides might move back to a category that lets pharmacies compound them again. That one statement sent the whole industry buzzing. And the story isn’t over. The FDA’s advisory committee has a meeting set for late July 2026 to sort out the details.

That means your business model could be legal one month and risky the next. Or the other way around. For a company trying to plan revenue, that’s a nightmare.

Every State Has Its Own Rules

Remember how cannabis was legal in Colorado but a crime two states over? Peptides have that same patchwork problem.

California has been the toughest, with its pharmacy board going after compounding operations again and again. Florida passed a law treating certain peptides like controlled precursors, with shipping paperwork due within 48 hours and felony charges for getting it wrong. Connecticut’s attorney general told weight-loss clinics to stop compounding certain drugs altogether. New York banned sales of muscle-building and weight-loss products to anyone under 18.

So the same peptide a pharmacy can legally make in Texas might be flat-out illegal to make in New York. If you want to sell across the whole country, you can’t just have one plan. You need a plan for every single state. That gets expensive fast.

The Raids Are Already Happening

This is the part that really takes me back. In the early 2010s, federal agents raided cannabis businesses that thought they were operating safely in the gray. Peptides are getting the same treatment now.

The FDA sent out more than 50 warning letters to peptide sellers and compounders across 2024 and 2025, and some of those escalated toward criminal referrals. In June 2025, the FDA raided the warehouse of Amino Asylum, and the company shut down on the spot. By March 2026, Peptide Sciences, which was doing an estimated $7.4 million a month in sales, quietly closed its doors before the government could come knocking. And the Justice Department already prosecuted Tailor Made Compounding and forced a $1.79 million forfeiture over unapproved peptides.

Selling a product with a “not for human use” label didn’t protect those companies. It didn’t protect cannabis businesses back then either.

The Government Keeps Reshuffling the Categories

Cannabis folks know all about the fight over rescheduling, where the DEA debates moving the plant from one legal category to another. Peptides have their own version of this.

The FDA sorts compounding ingredients into categories. Back in 2023, it pushed 19 popular peptides into a “do not compound” bucket. Now, as I mentioned, officials are talking about moving most of them back. One category means you can build a business. The other means you can’t. And the line between them keeps moving. Does that sound like a stable place to bet your savings?

Some Need a Prescription, Some Don’t

Cannabis split into medical and adult-use lanes, each with its own license and its own rules. Peptides have a similar split, just messier.

Collagen peptides and topical skincare peptides? Those sell freely as supplements and cosmetics, no prescription needed. The FDA-approved drugs like Ozempic? Always need a prescription. Compounded peptides like sermorelin sit in the middle, legal only with a patient-specific prescription. And a bunch of the trendy “research only” peptides have no legal path for human use at all.

So one peptide company might be running a clean supplement shop while another is one warning letter away from disaster. They both call themselves “peptide companies.” They are not the same business, and they shouldn’t be treated the same on the books.

The Banks Won’t Touch You

Ask any cannabis operator about banking and watch their face change. Getting a normal bank account was one of the hardest parts of the whole business.

Peptide companies are hitting the same wall. Most banks won’t offer a standard commercial account to a peptide business. The regulatory fog scares them off. So founders end up chasing down the handful of regional and online banks willing to work with them, usually at a higher cost. If you don’t know which doors to knock on, you can lose months.

Stripe, PayPal, and Square Will Drop You

And even once you sort out a bank, there’s the payment problem.

The big processors everyone uses to take credit cards, meaning Stripe, PayPal, and Square, routinely freeze or shut down peptide accounts. They approve you, you start selling, their systems flag you, and then you’re done. When that happens, your money can get held for 90 to 180 days, and you can land on an industry blacklist that makes opening a new account a real headache.

Imagine waking up to find your checkout is dead and six months of cash is frozen. For a growing company, that’s not a hiccup. That’s an emergency. Cannabis businesses learned this lesson the hard way, and peptide companies are learning it all over again.

Here’s My Honest Take

I’ll say the thing plainly. If you’re building a peptide company and you’re treating banking, compliance, and clean books as a problem for later, you’re making the exact mistake that wiped out a generation of early cannabis operators.

The companies that survived the cannabis shakeout weren’t always the ones with the best product. They were the ones who built real financial infrastructure early. They knew their numbers. They planned for frozen funds and lost accounts. They modeled what would happen if a rule changed overnight, because it always did.

Peptides are walking the same road. The demand is real and it’s huge. But the winners won’t be the founders moving the fastest. They’ll be the ones who saw the cannabis story play out and decided not to repeat it.